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To explore factors related to the placebo effect in patients with primary open-angle glau-
coma (POAG) or ocular hypertension (OH).
Methods
This was a retrospective cohort study of patients with POAG and patients with OH who
were treated with placebo. The patients’ data were extracted from two randomized, double-
masked, parallel, multicenter clinical trials (trial 1 and trial 2) in Japan. We explored the
baseline factors that were associated with the intraocular pressure (IOP)-lowering effect of
placebo ophthalmic solution after 4 weeks of instillation treatment at two time points by
using multivariable models. The time points were Hour 0 (between 08:30 and 10:30 before
instillation) and Hour 2 (within 1.5 to 2.5 h after instillation and by 12:30) at the baseline date
and after 4 weeks. The changes in IOP from baseline to 4 weeks at the two time points were
evaluated for the IOP-lowering effect induced by placebo instillation.
Results
Of the 330 patients included in the two trials, 89 patients were eligible for the analysis. The
results of the multivariable analysis for Hour 0 indicated a high IOP at the baseline date
(coefficient: 0.24, 95% confidence interval (CI): 0.02 to 0.46, P = 0.03), and the magnitude
of the IOP fluctuation at the baseline date (coefficient: 0.57, 95% CI: 0.24 to 0.90, P = 0.001)
was associated with the IOP-lowering effect after 4 weeks. With respect to Hour 2, the trial
type was associated with the IOP-lowering effect (coefficient: -1.15, 95% CI: -2.14 to -0.16,
P = 0.02).
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Conclusions
A large fluctuation in IOP during the day is associated with the IOP-lowering effect induced
by placebo in patients with POAG or OH. This finding would be helpful to researchers when
designing studies related to glaucoma in the early stages of clinical development of drugs.
Introduction
Glaucoma is a chronic, progressive optic neuropathy that presents as both optic disc damage
and visual field loss [1]. The type of glaucoma is determined by the condition of the iridocor-
neal angle [2]. Primary open-angle glaucoma (POAG) is associated with an open iridocorneal
angle and cupping of the optic-nerve head with corresponding loss of the visual field. Ocular
hypertension (OH), which is characterized by an intraocular pressure (IOP)>21 mmHg with-
out clinical signs, can progress into glaucoma if left untreated. The progression of visual field
loss in glaucoma is strongly related to IOP, and the reduction of IOP provides solid evidence
that the progression of the disease is slowing during treatment [3–6].
Several classes of ophthalmic solutions are available for the medical management of glau-
coma (e.g., prostaglandin analogs (PGAs) and beta-blockers) [7]. PGAs are generally used for
first line therapy because they have the greatest IOP lowering efficacy.
Various factors cause IOP fluctuations, including diurnal fluctuations, seasonal variations,
body position, and stress [8–12]. Moreover, the ranges of these fluctuations in patients with
glaucoma are larger than the ranges observed in healthy individuals. A large diurnal fluctuation
in IOP is a known risk factor for the progression of glaucoma [13]. For this reason, not only
the efficacy of an IOP-lowering agent, but also the degree of diurnal fluctuation is extremely
important when considering the appropriate treatment for glaucoma.
In general, a prospective, randomized, placebo-controlled trial is conducted to evaluate
glaucoma agents that are in the early stage of development [14, 15]. Although the placebo
should be ineffectual in establishing evidence of drug efficacy, placebo effects have been
reported in various diseases, including diseases in the ophthalmologic field (e.g., IOP reduction
among patients with glaucoma) [16–22]. It is possible that researchers underestimate a drug’s
ability to decrease IOP owing to placebo effects, which produce a bias towards the null. Thus,
the various factors associated with placebo effects should be considered when selecting study
subjects. However, currently, it is unclear which factors are related to placebo effects in patients
with glaucoma.
In this study, we aimed to investigate the baseline factors associated with the IOP-lowering
effect induced by placebo instillation after 4 weeks of treatment in patients with POAG or OH.
In particular, we focused on the patient characteristics, trial type, and IOP fluctuations that
were reported in two clinical trials.
Materials and Methods
Study design and data source
This study was a retrospective cohort study that utilized data from two randomized, double-
masked, placebo-controlled, multicenter, phase 2 clinical trials in Japan (SNJ-2022 [trial 1]
[23], SNJ-1656 [trial 2]). Trial 1 and trial 2 were conducted in 2006 and from 2009 to 2010,
respectively. These studies were registered in the UMIN-CTR, a clinical trials registry in Japan
(UMIN000019142, UMIN000018866).
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For trial 1, the key inclusion criteria for the selected subjects were patients with POAG or
OH, aged 20 years or older, who had an IOP of31 mmHg and a visual acuity of0.7. After
the screening examinations were performed, subjects were required to discontinue any current
glaucoma medication for an appropriate length of time as a washout period (e.g., for at least 4
weeks for prostaglandin analogs and beta-blocking agents). After the washout period, subjects
underwent additional examinations, and the day the examinations were performed was set as
the baseline date. The IOP at the baseline data was measured at two time points (Hour 0
[between 08:30 and 10:30] and Hour 2 [within 1.5 to 2.5 h after the measurement made at
Hour 0 and by 12:30]). We refer to Hour 0 and Hour 2 at baseline as “Week 0–0” and “Week
0–2,” respectively. In addition to the above-mentioned inclusion criteria, patients were also
required to complete the designated washout at the baseline date, and have an IOP of 18–31
mmHg (for patients with POAG) or 22–31 mmHg (for patients with OH) at Week 0–0. Sub-
jects meeting these inclusion criteria were then randomly allocated to groups that received
either 0.1% and 0.15% of SNJ-2022, or placebo twice daily (between 08:30 and 10:30, and
between 20:00 and 22:00) in both eyes for 4 weeks. After 2 and 4 weeks, the IOP was measured
at Hour 0 and Hour 2. We refer to Hour 0 and Hour 2 after 4 weeks as “Week 4–0” and “Week
4–2,” respectively. The IOP was measured twice at each time point, and the average was used
for evaluating the IOP-lowering effect in trial 1. However, in cases in which the difference
between the two IOP values was3 mmHg, another IOP measurement was required, and the
median value of the three was used for the evaluation. The higher IOP value from among the
obtained values for both eyes was selected as the study eye at Week 0–0. If the values were the
same, the right eye was selected.
The design of trial 2 was very similar to that of trial 1. The key differences in the inclusion
criteria between the two trials were the visual acuity (20/40) and the requirement of an IOP
confirmation visit prior to the baseline date in trial 2. In trial 2, each subject’s IOP was mea-
sured between 08:30 and 10:30 on the confirmation visit after the washout period and on
another day within 1 month of the confirmation visit (set as the baseline date if the subject met
the inclusion criteria). Subjects who exhibited a change in IOP of3 mmHg were then eligible
for the trial. The qualifying subjects were randomly allocated to groups that received 0.003%,
0.01%, or 0.03% of SNJ-1656 or placebo twice daily in both eyes for 4 weeks.
The composition of placebo solution used in study 1 is as follows: sodium chloride, potas-
sium chloride, calcium chloride, magnesium chloride, boric acid, borax, carmellose sodium,
sodium chlorite and purified water. On the other hand, the placebo solution used in study 2
was composed of the following: monobasic sodium phosphate dehydrate, sodium chloride,
benzalkonium chloride and purified water. The IOP was measured using Goldmann applana-
tion tonometer at all sites in the 2 clinical trials. Both trials were conducted in accordance with
the Declaration of Helsinki and were approved by the Institutional Review Board (IRB) of each
site.
For the present study, the eligibility criteria were patients who were randomly placed in the
placebo group and underwent placebo instillation for 4 weeks in trial 1 or trial 2. The study
protocol was approved by the Ethics Committee of Kyoto University Graduate School and the
Faculty of Medicine (R0104). All of the patients’ data were certified as anonymous.
Measurements
Subject characteristics were collected from a Case Report Form that was based on the medical
records and questionnaires from the patients in the two indicated trials. These two trials gath-
ered the following information from the patients: age, sex, vital signs, comorbidity, concomi-
tant drug, use of contact lenses, history of ocular surgery, eye examinations (e.g., visual acuity,
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IOP, visual field), laboratory tests, and adverse events. In the present study, we utilized the fol-
lowing patient information from the trials: age, sex, systolic blood pressure, diastolic blood
pressure, pulse rate, comorbidity (hypertension, diabetes, hyperlipidemia, and hyperuricemia),
diagnosis (POAG or OH), pretreatment drug for glaucoma, IOP, and time of IOP measure-
ments. The IOP data at Week 0–0, Week 0–2, Week 4–0, and Week 4–2 were collected in this
study.
Outcome
The primary outcome was the factors that were related to the change in IOP from the baseline
date to 4 weeks afterward, at the same time point (i.e., a change in IOP fromWeek 0–0 to
Week 4–0 and fromWeek 0–2 to Week 4–2).
Statistical analysis
The subject characteristics, including their age, sex, systolic blood pressure, diastolic blood
pressure, pulse rate, comorbidities (hypertension, diabetes, hyperlipidemia, and hyperurice-
mia), diagnosis, pretreatment drug for glaucoma, IOP, and time of IOP measurement, were
examined using descriptive statistics. These characteristics were summarized using means and
standard deviations for continuous variables and frequencies and percentages for categorical
variables. We compared the between-trial subject characteristics (change in IOP fromWeek
0–0 to Week 4–0 and fromWeek 0–2 to Week 4–2) using the Mann–Whitney U test.
Simple and multiple regression analyses were performed to explore the baseline factors asso-
ciated with the IOP-lowering effect induced by placebo instillation. Patient-specific variables
(age, sex, and comorbidities), characteristics of the IOP, and trial type (trial 1 or trial 2) were
included in the regression model as covariates.
The covariates of the IOP included the baseline IOP (Week 0–0 andWeek 0–2) and the dif-
ference in the two measurements obtained at Week 0–0 (as noted above, IOP values were con-
tinuously measured twice at each time point, and the difference in the two resulting IOP values
(Week 0–0 measure 1—Week 0–0 measure 2) was used as a covariate). Moreover, the change
in IOP fromWeek 0–0 to Week 0–2 was included in the model as a covariate of “IOP fluctua-
tion during the day.” The trial type was included to adjust for the differences between the two
trials (e.g., design, timing of implementation). Here, we excluded the diagnosis (POAG, OH)
from the analysis because it was not related to the change in IOP fromWeek 0–0 to Week 4–0
or fromWeek 0–2 to Week 4–2 in the univariate and multivariable regression models. Further-
more, the diagnosis exhibited a moderate correlation with the IOP at Week 0–0 (r = 0.552) and
Week 0–2 (r = 0.393).
The results are presented as the partial regression coefficient (PRC) and the corresponding
95% confidence intervals (CIs). P< 0.05 in a two-sided test was considered statistically signifi-
cant. Data management and statistical analyses were performed using SPSS software, version
22 (IBM).
Results
Of the 330 patients included in trial 1 and trial 2, 90 of them (44 in trial 1, 46 in trial 2) under-
went randomization to a placebo group. One subject who dropped out of trial 2 due to an
adverse event was excluded. Thus, a total of 89 subjects met our study eligibility criteria (Fig 1).
Table 1 shows the baseline characteristics of the patients included in the present study. Among
the 89 subjects, 58.4% were female, 28.1% had hypertension, 13.5% had diabetes, 21.3% had
hyperlipidemia, 51.7% were diagnosed with POAG, and 56.2% had received a pretreatment
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drug for glaucoma. No large differences were observed between trial 1 and trial 2 regarding the
baseline characteristics of the patients.
Table 2 describes the IOP and time of IOP measurement at each time point. The mean
change in IOP fromWeek 0–0 to Week 4–0 was 1.8 mmHg, while that fromWeek 0–2 to
Week 4–2 was 1.6 mmHg. The mean change rate fromWeek 0–0 to Week 4–0 was 7.8%, while
that fromWeek 0–2 to Week 4–2 was 7.2%. Regarding the change in IOP fromWeek 0–0 to
Week 0–2, 18.0% were<0 mmHg, 40.4% were from 0–1 mmHg, 28.1% were between 1–2
mmHg, and 13.5% were2 mmHg. The times of IOP measurement were approximately the
same at the baseline date and after 4 weeks. Regarding the differences between the trials, the
change in IOP fromWeek 0–0 to Week 4–0 in trial 2 (1.3 mmHg) was smaller than that in trial
1 (2.2 mmHg) (P = 0.048), and the change in IOP fromWeek 0–2 to Week 4–2 in trial 2 (1.0
mmHg) was also smaller than that in trial 1 (2.2 mmHg) (P = 0.03).
Table 3 shows the associations between the change in IOP fromWeek 0–0 to Week 4–0 and
the subject characteristics. In the univariate analysis, diabetes (coefficient: -1.46, 95% CI: -2.85
to -0.07, P = 0.04) and the change in IOP fromWeek 0–0 to Week 0–2 (coefficient: 0.65, 95%
CI: 0.33 to 0.98, P< 0.001) were significantly related to the change in IOP. In the multivariable
analysis, the change in IOP was significantly associated with the IOP at Week 0–0 (coefficient:
0.24, 95% CI: 0.02 to 0.46, P = 0.03) and the change in IOP fromWeek 0–0 to Week 0–2 (coef-
ficient: 0.57, 95% CI: 0.24 to 0.90, P = 0.001). These results imply that an increase of 1 mmHg
at Week 0–0 increased the IOP-lowering effect caused by placebo instillation by 0.24 mmHg,
and that an increase of 1 mmHg in the IOP fromWeek 0–0 to Week 0–2 increased the IOP-
lowering effect by 0.57 mmHg.
Table 4 presents the associations between the change in IOP fromWeek 0–2 to Week 4–2
and the subject characteristics. In the univariate analysis, the change in IOP was significantly
associated with hyperlipidemia (coefficient: -1.23, 95% CI: -2.44 to -0.01, P = 0.05) and trial
type (coefficient: -1.21, 95% CI: -2.19 to -0.22, P = 0.02). In the multivariable analysis, signifi-
cant associations were noted between the change in IOP and trial type (coefficient: -1.15, 95%
Fig 1. Flow diagram of the subject selection process.
doi:10.1371/journal.pone.0156706.g001
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CI: -2.14 to -0.16, P = 0.02). Specifically, trial 2 was less likely than trial 1 to reduce the IOP via
placebo instillation by 1.15 mmHg.
Discussion
This is the first study to use the data from randomized, double-masked, parallel comparison,
multicenter clinical trials involving patients with POAG or OH to investigate the factors that
influence the IOP-lowering effect induced by placebo instillation. Our results showed that the
IOP at Week 0–0 and the change in IOP fromWeek 0–0 to Week 0–2 were associated with the
change in IOP fromWeek 0–0 to Week 4–0. These associations imply that a higher IOP at
Week 0–0 and a large change in IOP fromWeek 0–0 to Week 0–2 tended to produce a large
IOP-lowering effect at Week 4–0 by placebo instillation. Meanwhile, the trial type was associ-
ated with the change in IOP fromWeek 0–2 to Week 4–2.
The diurnal variation in IOP is a well-known phenomenon that occurs both in the eyes of
patients with glaucoma and in healthy individuals, with the IOP being high early in the morn-
ing and low in the evening [24–26]. Considering that the IOP gradually decreases from morn-
ing to noon, the change in IOP that was observed fromWeek 0–0 to Week 0–2 was likely
related to the diurnal variation, thus the patients with large IOP changes between these two
measurement times would have large diurnal variations in IOP. Clearly, the IOP in patients
Table 1. Baseline characteristics of study participants (N = 89).
Trial 1 (N = 44) Trial 2 (N = 45) Total (N = 89)
N % N % N %
Age, in yrs, mean (±SD) 54.6 15.9 57.5 13.0 56.1 14.5
Female sex 28 63.6 24 53.3 52 58.4
Blood pressure, Pulse rate*
SBP, in mmHg, mean (±SD) 131 18.8 128 19.1 129 18.9
DBP, in mmHg, mean (±SD) 78 11.6 76 11.8 77 11.7
Pulse rate, in pulses/min, mean (±SD) 73 12.0 73 12.1 73 12.0
Comorbidity†
Hypertension 10 22.7 15 33.3 25 28.1
Diabetes 6 13.6 6 13.3 12 13.5
Hyperlipidemia 7 15.9 12 26.7 19 21.3
Hyperuricemia 0 0.0 3 6.7 3 3.4
Diagnosis
POAG 22 50.0 24 53.3 46 51.7
OH 22 50.0 21 46.7 43 48.3
Pretreatment drug 25 56.8 25 55.6 50 56.2
Prostaglandin analogs 21 47.7 19 42.2 40 44.9
Beta-blocking agents 6 13.6 7 15.6 13 14.6
Alpha-beta-blocking agents 2 4.5 1 2.2 3 3.4
Carbonic anhydrase inhibitors 2 4.5 5 11.1 7 7.9
Pilocarpine Hydrochloride 0 0.0 1 2.2 1 1.1
Abbreviations: SD, standard deviation; SBP, systolic blood pressure; DBP, diastolic blood pressure; POAG, primary open-angle glaucoma; OH, ocular
hypertension.
*Value at Week 0–0.
†Comorbidity was deﬁned as having both diagnoses and therapeutic medication.
doi:10.1371/journal.pone.0156706.t001
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with large diurnal variations can easily change at any moment. In addition, the IOP fluctua-
tions that occurred between Week 0 and Week 4 are presumed to be one of the key factors
causing the change in IOP after 4 weeks. Indeed, a previous study on glaucoma patients
reported that the IOP fluctuated on individual days [27].
Table 3. Univariate andmultivariable regression models at Hour 0.
Univariate analysis Multivariable analysis
PRC 95% CI P PRC 95% CI P
Age, in yrs -0.03 -0.06 0.01 0.11 -0.00 -0.04 0.03 0.82
Female sex 0.48 -0.51 1.46 0.34 0.75 -0.21 1.72 0.13
Comorbidity
Hypertension -0.65 -1.72 0.43 0.24 0.19 -0.92 1.29 0.74
Diabetes -1.46 -2.85 -0.07 0.04 -1.21 -2.62 0.20 0.09
Hyperlipidemia -1.14 -2.30 0.03 0.06 -0.50 -1.74 0.74 0.42
IOP
IOP (Week 0–0) 0.22 -0.01 0.44 0.06 0.24 0.02 0.46 0.03
Difference between repeated measurements (Week 0–0)* -0.13 -0.95 0.68 0.75 -0.55 -1.31 0.21 0.15
Change in IOP from Week 0–0 to Week 0–2† 0.65 0.33 0.98 <0.001 0.57 0.24 0.90 0.001
Trial type (Trial 2) ‡ -0.85 -1.81 0.11 0.08 -0.85 -1.75 0.05 0.07
R2 = 0.296.
Abbreviations: PRC, partial regression coefﬁcient; CI, conﬁdence interval; IOP, intraocular pressure; R2, coefﬁcient of determination.
*Change in IOP between the 1st and 2nd measurements at Week 0–0 (1st measured value—2nd measured value).
†Week 0–0—Week 0–2.
‡The reference group consisted of the subjects in trial 1.
doi:10.1371/journal.pone.0156706.t003
Table 4. Univariate andmultivariable regression models at Hour 2.
Univariate analysis Multivariable analysis
PRC 95% CI P PRC 95% CI P
Age, in yrs -0.01 -0.05 0.02 0.53 -0.01 -0.05 0.03 0.66
Female sex 0.70 -0.33 1.72 0.18 0.69 -0.38 1.76 0.20
Comorbidity
Hypertension 0.15 -0.99 1.28 0.80 0.61 -0.61 1.83 0.33
Diabetes -1.07 -2.55 0.40 0.15 -0.93 -2.48 0.63 0.24
Hyperlipidemia -1.23 -2.44 -0.01 0.05 -1.23 -2.60 0.14 0.08
IOP
IOP (Week 0–2) 0.20 -0.01 0.42 0.07 0.23 -0.01 0.47 0.06
Difference between repeated measurements (Week 0–0)* -0.09 -0.94 0.77 0.84 -0.49 -1.33 0.35 0.25
Change in IOP from Week 0–0 to Week 0–2† -0.34 -0.71 0.02 0.06 -0.20 -0.61 0.20 0.32
Trial type (Trial 2) ‡ -1.21 -2.19 -0.22 0.02 -1.15 -2.14 -0.16 0.02
R2 = 0.221.
Abbreviations: PRC, partial regression coefﬁcient; CI, conﬁdence interval; IOP, intraocular pressure; R2, coefﬁcient of determination.
*Change in IOP between the 1st and 2nd measurements at Week 0–0 (1st measured value—2nd measured value).
†Week 0–0—Week 0–2.
‡The reference group was the subjects in trial 1.
doi:10.1371/journal.pone.0156706.t004
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Other possible factors for the change in IOP fromWeek 0–0 to Week 4–0 include the
mental stress associated with participating in the clinical trial and the patients’ desire to
respond to treatment. First, the lower measured IOP values observed at 4 weeks, relative to
those obtained at baseline, may be related to a mental stress-induced increase in IOP at the
baseline date. Although the change in IOP fromWeek 0–0 to Week 4–0 was related to the
change in IOP fromWeek 0–0 to Week 0–2, the change in IOP fromWeek 0–2 to Week 4–2
was not related to this factor. The reason for this difference may be that the influence of men-
tal stress at Week 0–2 was weaker than that at Week 0–0, as Week 0–2 was the second mea-
surement at the baseline date. The subjects would become habituated to IOP measurement.
Thus, the IOP at Week 0–2 might not have included an IOP increase; accordingly, the change
in IOP fromWeek 0–2 to Week 4–2 might be smaller than the IOP change fromWeek 0–0 to
Week 4–0.
Second, the patients’ desire to have a beneficial response to therapy may have also played a
role in the IOP-lowering effect at 4 weeks. Indeed, it is well-known that this factor causes a pla-
cebo effect [28].
As for why the IOP at Week 0–0 affected the change in IOP fromWeek 0–0 to Week 4–0,
this could be related to regression towards the mean [29]. In fact, the IOP at Week 0–0 was
high, while the IOP at Week 4–0 was lower than that at Week 0–0. However, a high IOP at
Week 0–2 was not significantly associated with the IOP-lowering effect at Week 4–2, which
had a similar tendency as that fromWeek 0–0 to Week 4–0.
There were several design differences between trial 1 and trial 2; the key difference was the
inclusion criteria for the IOP value. In particular, trial 2 applied more stringent criteria than
trial 1, in that the change in IOP from the IOP confirmation visit to Week 0–0 had to be within
3 mmHg. Hence, trial 2 excluded those patients with large changes in IOP.
According to the multivariable analysis, the IOP fluctuations that occurred between Week 0
andWeek 4 is one of the key factors causing the change in IOP; thus, it is presumed that
patients without this factor would experience a lower placebo effect than would patients with
this factor. Therefore, as a result of the above noted differences in the trial designs, the number
of patients who were at risk of experiencing the placebo effect was likely diminished in trial 2,
resulting in less of an IOP-lowering effect. Interestingly, a past clinical trial included a criterion
relevant to the difference in IOP between the two measurement dates [14]. Although trial type
was not significantly associated with the IOP-lowering effect at Week 4–0, the tendency was
similar to that observed at week 4–2. Although, hyperlipidemia affected the change in IOP in
the univariate regression models, it is less likely that IOP would be influenced by this factor.
This is because hyperlipidemia was not significantly associated with the change in IOP in the
multivariable regression model.
Although some constituents of each placebo solution were different, we believe that the IOP
would not be influenced by these components as these are normally found in eye drops. The
adverse event that caused drop out of the patients in trial 2 was related to placebo instillation.
However, the AE was allergic conjunctivitis, which would not influence the evaluation of IOP
change in this study.
A previous study on glaucoma patients reported that the regression towards the mean
might influence the placebo effect [22]. The results of the present study are not consistent with
the findings of a previous study, which showed that setting a separate day entry criterion of
IOP did not effectively restrain the placebo effect [20]. However, because the previous study
only used averages rather than pulling the data from each patient individually, the obtained
results would be expected to differ from those of the current study. In particular, the use of
only summaries of published data, rather individual patient data [20], meant the association
between the glaucoma patients’ individual characteristics and placebo effects could not be fully
Factors Influencing Placebo Effect in Glaucoma Patients
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ascertained. In this regard, the strength of the present study was the inclusion of individual-
level patient data from the clinical trials.
Our study has several limitations. Although the present study was conducted using data from
two clinical trials, the sample size was limited. Accordingly, the small sample size limits the gen-
eralizability of our results. Secondly, we might not have been able to adjust for all of the potential
confounding factors (e.g., personality, lifestyle), as the trials did not necessarily collect informa-
tion on all of these variables, hence they were not available to us. For example, a previous study
reported that changes in blood pressure are positively associated with IOP [30], which might
account for the changes in IOP observed in our study. Although we confirmed that the large fluc-
tuations in IOP are related to the low IOP with placebo instillation, it is unclear whether the low
IOP could be produced with no treatment, and hence, further research using more variables is
needed. A prospective study, especially a crossover study, would be useful to identify the factors
related to placebo effect. In the same cohort of patients, a comparison of change in IOP with
treatment (viz. active agents, placebo, or no treatment) would clear the relationship between pla-
cebo instillation, IOP fluctuation, and IOP change. Nonetheless, the present study has some ben-
efits because this retrospective cohort study with secondary use of data could give results without
expenditure of much time and money. Thirdly, our study was conducted using only Japanese
patients, which is significant because the IOP is lower in Japanese individuals than it is in West-
erners [31]. In several patients, the IOP at the baseline date was less than 21 mmHg, which is the
upper limit for normal IOP. Thus, when considering expanding the study to other settings such
as the U.S., it might be necessary to analyze patients with higher IOP values. Fourth, this study
included patients who had undergone drug treatment for glaucoma and patients who were
untreated. Although the patients receiving pretreatment drug for glaucoma had general washout
periods in clinical trial before placebo instillation, the IOP-lowering effect induced by placebo
might be underestimated in the pretreatment drug recipients. This is because there was a patient
who displayed the drug effect for a long period of time even after discontinuation of the drug
[32]. Because long washout periods may contribute to disease progression, it might be better to
confirm the effect of placebo in patients with untreated glaucoma in future.
Conclusions
The current study suggests that large fluctuations in IOP are related to the low IOP that is
induced by placebo in patients with POAG or OH. This finding may help researchers design
studies for glaucoma agents that are in the early stage of development. For example, establish-
ing a visit to confirm diurnal IOP patterns in order to exclude patients with large IOP magni-
tudes would lead to a more accurate evaluation of the IOP-lowering effect of the drug. As a
large difference in effectiveness between an active agent and placebo permits a smaller sample
size in clinical trials, this would reduce both the sample size and cost for clinical trials. How-
ever, additional studies with large sample sizes and many variables are necessary to expand the
generalizability of our study.
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